AbelZeta Unveils C-CAR168 Presentation Details at LUPUS 2025

Author: Lucas Young Updated: 05-16-2025 09:12 AM

Exciting Developments from AbelZeta Pharma for LUPUS 2025

AbelZeta Pharma, Inc. is making waves in the biopharmaceutical industry with its innovative approach to treating autoimmune diseases. The company has recently announced the acceptance of an abstract for its groundbreaking therapy, C-CAR168, to be presented at the 16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025). This prestigious event will take place in Toronto, celebrating advancements in lupus therapies.

C-CAR168: A New Hope for Autoimmune Diseases

C-CAR168 is an autologous bi-specific CAR-T therapy designed to target key antigens associated with autoimmune diseases. By focusing on CD20 and B-cell maturation antigens (BCMA), this therapy shows promise for patients suffering from conditions such as resistant Lupus Nephritis and Systemic Lupus Erythematosus (SLE). With the FDA's clearance for its Investigational New Drug (IND) application, AbelZeta is poised to move forward into Phase 1 clinical development.

Presentation Details at LUPUS 2025

The oral presentation for C-CAR168 is scheduled for May 22, and will highlight its clinical impact in treating refractory Lupus Nephritis. Here are the key details you need to know:

Abstract Title: Clinical Impact of C-CAR168, A Novel Anti-CD20/BCMA Composite Autologous CAR-T Therapy, in Refractory Lupus Nephritis
Session Title: Abstract Concurrent Session 04: Advancing Lupus Therapies and Insights
Presentation Time: May 22, from 14:10 to 14:20
Presenter: Nan Shen, M.D., PhD, Principal Investigator
Location: Westin Harbour Castle, Toronto, Ontario
Room: Queens Quay

Additional Insights from AbelZeta Leadership

Adding to the event’s excitement, Barbara Mittleman, the Vice President of Clinical Development at AbelZeta, will also present at a scientific session on cell therapy in lupus. Scheduled for May 23, her talk will explore the current landscape of cell therapy in SLE and discuss the ongoing challenges and opportunities in this field.

Session Name: Cell Therapy in Lupus
Session Time: May 23, from 11:35 to 12:20
Room: Pier 2&3

About AbelZeta Pharma, Inc.

AbelZeta is a prominent player in the biopharmaceutical sector, dedicated to advancing cell-based therapeutic products. With bases in Rockville and Shanghai, the company focuses on creating innovative solutions that utilize the body’s immune system to combat various diseases, from hematological malignancies to solid tumors and beyond. Their commitment to research and development is evident in their GMP facilities, where they push the boundaries of CAR-T and TIL therapies.

Frequently Asked Questions

What is C-CAR168 and its significance?

C-CAR168 is an innovative CAR-T therapy that targets CD20 and BCMA, aiming to treat autoimmune conditions like Lupus Nephritis.

When and where is the LUPUS 2025 event?

The LUPUS 2025 Congress is set to take place from May 21-24 in Toronto, Canada.

Who will present at this congress?

Nan Shen, M.D., PhD, will present on C-CAR168, and Barbara Mittleman will speak on cell therapy in lupus.

What are the focuses of the presentations?

The presentations will cover advances in lupus therapies and the specific impact of C-CAR168 on Lupus Nephritis.

How does AbelZeta contribute to biopharmaceutical advancements?

AbelZeta is dedicated to developing proprietary therapeutic products that leverage the immune system to treat various diseases.

About The Author

Even at just 28 years old, Lucas Young has made a name for himself as a writer and financial expert. Lucas is a gifted communicator of difficult financial ideas and has written a number of well-received books and articles that appeal to both new and experienced investors. The financial world has come to rely on his perceptive analysis and useful counsel. Many people have been enabled to make wise investment decisions by Lucas's commitment to financial literacy and his ability to demystify the complexities of the market. Lucas is still dedicated to advising and teaching people on their financial journeys as he shares his knowledge.

Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.